Phreesia (NYSE:PHR) Shares Gap Up on Earnings Beat

Phreesia, Inc. (NYSE:PHR)’s stock price gapped up before the market opened on Thursday following a stronger than expected earnings report. The stock had previously closed at $9.13, but opened at $10.78. Phreesia shares last traded at $9.7710, with a volume of 468,672 shares traded.

The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Phreesia had a net margin of 0.48% and a return on equity of 3.23%. The firm had revenue of $130.94 million for the quarter, compared to the consensus estimate of $130.08 million. During the same period in the previous year, the firm earned ($0.07) EPS. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year.

Trending Headlines about Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Phreesia reported fiscal Q1 2027 EPS of $0.05, topping the $0.02 consensus estimate, while revenue of $130.94 million slightly beat expectations and rose 12.9% year over year.
• Positive Sentiment: Management guided FY2027 revenue to $510 million-$520 million and kept adjusted EBITDA guidance at $125 million-$135 million, suggesting continued growth and profitability progress.
• Neutral Sentiment: Several firms reiterated reminders about the July 13, 2026 lead-plaintiff deadline in the pending class action, keeping legal overhang news in focus for investors.
• Negative Sentiment: The newly highlighted class action alleges Phreesia made misleading statements about revenue growth projections and downplayed slowing growth in Network Solutions, which could increase investor concern about future disclosures and litigation risk. Article title

Wall Street Analyst Weigh In

Several research firms recently commented on PHR. Citizens Jmp reiterated a “market perform” rating on shares of Phreesia in a research note on Wednesday, April 1st. BMO Capital Markets decreased their price target on Phreesia from $32.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 31st. Wall Street Zen cut shares of Phreesia from a “buy” rating to a “hold” rating in a report on Saturday, April 4th. Needham & Company LLC lowered their target price on shares of Phreesia from $35.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Finally, Barclays restated an “equal weight” rating and set a $10.00 price target (down from $24.00) on shares of Phreesia in a research report on Thursday, May 14th. Ten equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $18.71.

Insiders Place Their Bets

In other Phreesia news, General Counsel Allison C. Hoffman sold 6,176 shares of Phreesia stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $9.06, for a total transaction of $55,954.56. Following the sale, the general counsel directly owned 157,309 shares of the company’s stock, valued at approximately $1,425,219.54. The trade was a 3.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Linetsky sold 8,332 shares of Phreesia stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $8.07, for a total value of $67,239.24. Following the sale, the insider owned 224,056 shares in the company, valued at $1,808,131.92. This represents a 3.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 50,493 shares of company stock worth $461,983. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Several hedge funds have recently bought and sold shares of the business. Pale Fire Capital SE purchased a new position in shares of Phreesia during the first quarter valued at approximately $72,481,000. Granahan Investment Management LLC lifted its holdings in shares of Phreesia by 73.8% during the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock valued at $40,601,000 after purchasing an additional 1,018,987 shares in the last quarter. Prosight Management LP purchased a new stake in shares of Phreesia during the 4th quarter valued at about $16,533,000. Millennium Management LLC grew its position in Phreesia by 730.7% in the 3rd quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock worth $25,028,000 after purchasing an additional 936,033 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Phreesia during the fourth quarter valued at $15,213,000. Institutional investors own 92.10% of the company’s stock.

Phreesia Stock Up 6.7%

The stock has a market cap of $601.83 million, a PE ratio of 325.00 and a beta of 0.89. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.53 and a current ratio of 1.53. The company’s 50-day moving average price is $9.53 and its 200 day moving average price is $13.69.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.